---
title: "Gedatolisib Displays Early Efficacy in mCRPC and Pretreated HER2+ Breast Cancer"
description: "Gedatolisib shows clinical activity in prostate and HER2+ breast cancer patients."
pubDate: "2025-06-30"
category: "business"
image: "https://cdn.sanity.io/images/0vv8moc6/onclive/b92f7430b0277068da75332136b852536c847f54-1920x1080.jpg?fit=crop&auto=format"
slug: "gedatolisib-displays-early-efficacy-in-mcrpc-and-pretreated-her2-breast-cancer"
source: "OncLive"
lang: "en"
---

Gedatolisib generated clinical activity in metastatic castration-resistant prostate cancer and HER2-positive breast cancer.

Image Credit: Â© Axel Kock - stock.adobe.com
Treatment with the pan-PI3K and mTORC1/2 inhibitor gedatolisib (PF-05212384) generated clinical activity in patients with metastatic castration-resistant prostate cancer (mCRPC) and patients with metastatic... [4523 chars]

[Kaynak](https://www.onclive.com/view/gedatolisib-displays-early-efficacy-in-mcrpc-and-pretreated-her2-breast-cancer)
